YASOO Health- Completes Phase I NIH Grant Nutrient and Phytochemical Research Protocol for Cystic Fibrosis

Johnson City, TN - Yasoo Health has successfully completed a Phase I nutrient and phytochemical research protocol for Cystic Fibrosis funded by the National Institutes of Health (NIH). Yasoo Health is pursuing a $750,000 NIH Phase II NIH grant to further its research in disease treatment for Cystic Fibrosis. Cystic Fibrosis (CF) is a genetic disease affecting approximately 30,000 children and adults in the United States and leads to life-threatening lung infections. A defective gene causes secretions that obstruct the pancreas, preventing digestive enzymes from reaching the intestines to help break down and absorb food.

“This award from the National Institutes of Health enables Yasoo Health to validate the concept of overcoming malabsorption and improving the quality of life of Cystic Fibrosis patients”, stated Dr. Andreas Papas, President of Yasoo Health. “We are excited about this opportunity to validate a unique technology that can be applied in the management of other chronic diseases”.

ABOUT Yasoo Health:
Yasoo Health (Yasoo meaning "Good Health" in Greek) is a nutraceutical company with offices in Johnson City, TN, and Nicosia, Cyprus. Yasoo Health was the first company to move into the East Tennessee State University (ETSU) Innovation Laboratory, which links entrepreneurs with investors to facilitate the creation of technology-based startup and spin-off companies. YASOO seeks to develop proprietary, disease-specific products based on nutrients and natural compounds that will aid in the effective management of chronic diseases.

Yasoo Health pioneered the Vitamin E Factor™ concept to highlight the importance of the complete Vitamin E family of 8 compounds. Most commercially available Vitamin E consisted of alpha-tocopherol, only one of the 4 tocopherols and 4 tocotrienols that make up natural Vitamin E. Scientists are now discovering the benefits of the other members of vitamin E especially gamma-tocopherol and the tocotrienols. YASOO was the first to introduce products that contain the complete family of tocopherols plus tocotrienols in their natural form as found in our food.

The Company’s business model includes both a traditional nutritional supplement line and a proprietary, disease specific product line. The traditional nutritional supplement line includes premium nutritional supplements and a skin cream specially formulated on the basis of the latest science and clinical research to promote wellness and prevent disease. YASOO plans to expand its line of non-proprietary products to meet key market needs.

Yasoo Health is developing proprietary technologies for the management of chronic diseases associated with malabsorption such as cystic fibrosis, cholestasis, Crohn's and ulcerative colitis (IBD), alcoholic hepatitis and AIDS.

Yasoo president, Dr. Andreas M. Papas holds a Ph.D. in Nutritional Biochemistry and combines 25 years of academic and industrial experience in nutraceuticals. Dr. Papas is currently an Adjunct Professor at the College of Medicine at East Tennessee State University and a Senior Scientific Advisor of the Cancer Prevention Institute at Harvard’s School of Epidemiology. He is the author of The Vitamin E Factor (HarperCollins, 1999) and editor of the scientific book Antioxidant Status, Diet, Nutrition and Health (CRC Press, 1998).

Professor K, C. Nicolaou, YASOO Scientific Advisory Board Chairman, is Chairman of the Chemistry Department at the Scripps Research Institute in La Jolla, San Diego. Dr. Nicolaou is a well renowned authority in chemical synthesis and chemical biology with over 500 scientific publications, two books, and sixty patents. Dr Michael Nicolaou is Associate Director, Product development of Epimmune Inc., a California-based biotechnology Company.

In July 2002, Yasoo Health received $4.6 million in venture capital financing. In 2002 Yasoo Health received a $100,000 NIH Grant for Phase I Cystic Fibrosis research. NIH Phase II grant funding, which will include extensive clinical evaluation, is presently being pursued.

For more information please contact:
Wes Burgar
International Director, Sales & Marketing
YASOO Health Inc.
P.O. Box 3608
Johnson City, TN 37602-3608
888-469-2766 (USA only, toll free)
423-926-3490 (USA and international)

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.